Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase zeta catalytic subunit (REV3-like) is the largest and catalytically active component of Pol ζ, a B-family DNA polymerase that is crucial for translesion DNA synthesis—a pathway allowing DNA replication past lesions or damage that would otherwise stall replication forks. REV3L forms a multi-subunit enzyme complex with REV7 (also MAD2L2), POLD2, and POLD3, enabling tolerance to diverse DNA lesions and promoting genome stability in eukaryotic cells. The holoenzyme has a pentameric ring-like structure, and unlike other B-family DNA polymerases, the exonuclease domain of REV3L is inactive (lacks proofreading). Loss of REV3L function leads to genomic instability and cell death, while its activity is leveraged by cancer cells to survive genotoxic stress, making it a promising—but therapeutically challenging—target.
Extension step of translesion synthesis—REV3L (Pol ζ) extends primers across beyond replication-blocking DNA lesions, often working with other TLS polymerases (e.g., REV1, Pol η)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase zeta catalytic subunit (REV3-like) (REV3L or Rev3).